» Articles » PMID: 35587943

Characterization of Proteolytic Degradation Products of Vaginally Administered Bovine Lactoferrin

Overview
Journal PLoS One
Date 2022 May 19
PMID 35587943
Authors
Affiliations
Soon will be listed here.
Abstract

When bovine lactoferrin (bLF) contacts human vaginal fluid (VF) it is subjected to proteolytic degradation. This report describes fragmentation patterns of bLF dosed vaginally in clinical trials or incubated ex vivo with VF. A consensus pattern of fragments was observed in samples from different women. The 80 kDa bLF molecule is initially cleaved between its homologous 40 kDa domains, the N-lobe and C-lobe, and then degraded into sub-fragments and mixtures of small peptides. We characterized this fragmentation process by polyacrylamide gel electrophoresis, western blotting, chromatographic separation, and mass spectral sequence analysis. Common to most VF fragmentation patterns were large amounts of an N-lobe 37 kDa fragment and a C-lobe 43 kDa fragment resulting from a single cleavage following tyrosine 324. Both fragments possessed full sets of iron-ligand amino acids and retained iron-binding ability. In some VF samples, alternative forms of large fragments were found, which like the 37+43 kDa pair, totaled 80 kDa. These included 58+22 kDa, 18+62 kDa, and 16+64 kDa forms. In general, the smaller component was from the N-lobe and the larger from the C-lobe. The 18+62 kDa pair was absent in some VF samples but highly abundant in others. This variability suggests multiple endopeptidases are involved, with the 18 kDa fragment's presence dependent upon the balance of enzymes. Further action of VF endopeptidases produced smaller peptide fragments, and we found evidence that exopeptidases trimmed their N- and C-termini. The 3.1 kDa antimicrobial peptide lactoferricin B was not detected. These studies were facilitated by a novel technique we developed: tricolor western blots, which enabled simultaneous visualization of N- and C-terminal epitopes.

Citing Articles

Proteolysis of vaginally administered bovine lactoferrin: clearance, inter-subject variability, and implications for clinical dosing.

Hopp T, Matthews M, Spiewak K, Athanasiou Z, Blackmore R, Gelbfish G Biometals. 2022; 36(3):531-547.

PMID: 36580179 PMC: 10182156. DOI: 10.1007/s10534-022-00481-7.


Antimicrobial activity of bovine lactoferrin against species clinical isolates.

Pino A, Mazza T, Matthews M, Castellana S, Caggia C, Randazzo C Front Microbiol. 2022; 13:1000822.

PMID: 36419418 PMC: 9678186. DOI: 10.3389/fmicb.2022.1000822.


Effect of in vitro gastrointestinal digestion on the antibacterial activity of bioactive dairy formulas supplemented with lactoferrin against Cronobacter sakazakii.

Abad I, Serrano L, Graikini D, Perez M, Grasa L, Sanchez L Biometals. 2022; 36(3):667-681.

PMID: 36335546 PMC: 10182125. DOI: 10.1007/s10534-022-00459-5.

References
1.
Paesano R, Torcia F, Berlutti F, Pacifici E, Ebano V, Moscarini M . Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol. 2006; 84(3):377-80. DOI: 10.1139/o06-040. View

2.
Baker H, Baker E . Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals. 2004; 17(3):209-16. DOI: 10.1023/b:biom.0000027694.40260.70. View

3.
Mata L, Castillo H, Sanchez L, Puyol P, Calvo M . Effect of trypsin on bovine lactoferrin and interaction between the fragments under different conditions. J Dairy Res. 1994; 61(3):427-32. DOI: 10.1017/s0022029900030867. View

4.
Wang B, Timilsena Y, Blanch E, Adhikari B . Lactoferrin: Structure, function, denaturation and digestion. Crit Rev Food Sci Nutr. 2017; 59(4):580-596. DOI: 10.1080/10408398.2017.1381583. View

5.
van der Kraan M, Groenink J, Nazmi K, Veerman E, Bolscher J, Nieuw Amerongen A . Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides. 2004; 25(2):177-83. DOI: 10.1016/j.peptides.2003.12.006. View